Atomo Diagnostics Limited (ASX:AT1) Announces National Scale-Up and NZ Launch
National Scale-Up of HIV Self-Test Vending Machines
Atomo Diagnostics is expanding its CONNECT Programme to provide free HIV self-tests through vending machines across Australia. The initial order from Thorne Harbour Health is valued at approximately $230,000, with further funding secured for expanded testing in 2026.
International Expansion
Atomo’s HIV Self-Test has launched in New Zealand through Chemist Warehouse, the largest retail pharmacy chain in the country, following its registration for import.
Executive Comments
CEO John Kelly stated, “We are excited about the growing adoption of HIV Self-Testing as critical to the government’s efforts fight against HIV and look forward to continuing to work with THH and others to ensure that tests are readily available in the community where needed.” Mr Kelly added “We are also pleased to be able to expand our supply of the Atomo HIV Self-Test into the New Zealand market and we continue to look for international markets where we can secure meaningful pharmacy retail channel access for our HIV product.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
